Duloxetine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Obsessive Compulsive Disorder

Conditions

Obsessive Compulsive Disorder

Trial Timeline

Dec 1, 2005 → Dec 1, 2013

NCT ID

NCT00464698

About Duloxetine

Duloxetine is a approved stage product being developed by Eli Lilly for Obsessive Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00464698. Target conditions include Obsessive Compulsive Disorder.

What happened to similar drugs?

4 of 9 similar drugs in Obsessive Compulsive Disorder were approved

Approved (4) Terminated (1) Active (4)

🔄Fluvoxamine maleate + PlaceboAbbViePhase 3

🔄quetiapine fumarate + SSRI/ClomipramineAstraZenecaPhase 3

✅Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)NovartisApproved

✅pregabalin + PlaceboPfizerApproved

✅EscitalopramLundbeckApproved

✅Escitalopram + Placebo oral tabletLundbeckApproved

🔄Troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01391221	Approved	UNKNOWN	Jul 1, 2011	Aug 1, 2013	Major Depression
NCT01363284	Pre-clinical	Completed	Jun 1, 2010	Aug 1, 2012	Diabetes
NCT01089621	Approved	Withdrawn	Mar 1, 2010	Aug 1, 2010	Fibromyalgia
NCT01051466	Approved	Completed	Jan 1, 2010	Mar 1, 2013	Major Depressive Disorder
NCT00989157	Phase 3	Completed	Sep 1, 2009	Nov 1, 2012	Bariatric Surgery
NCT01074151	Pre-clinical	Completed	Jul 1, 2009	Jul 26, 2021	Pregnancy
NCT00889369	Approved	UNKNOWN	May 1, 2009	Jun 1, 2012	Major Depressive Disorder
NCT01754493	Approved	Completed	Dec 1, 2008	Dec 1, 2014	Major Depression
NCT01028352	Pre-clinical	Completed	Oct 1, 2008	Oct 1, 2011	Breast Cancer
NCT00696774	Approved	Completed	Jun 1, 2008	Jul 1, 2009	Depressive Disorder, Major
NCT00532480	Approved	Completed	Sep 1, 2007	Apr 1, 2009	Major Depression
NCT00529789	Phase 2	Completed	Aug 1, 2007	Sep 1, 2008	Major Depressive Disorder
NCT00696293	Approved	Completed	May 1, 2007	Apr 1, 2010	Major Depressive Disorder
NCT00517985	Approved	Completed	Feb 1, 2007	Jun 1, 2008	Major Depressive Disorder
NCT00398632	Approved	Terminated	Nov 1, 2006	Apr 1, 2009	Depression
NCT00401258	Approved	Completed	Nov 1, 2006	Feb 1, 2008	Irritable Bowel Syndrome
NCT00438971	Approved	Completed	Aug 1, 2006	Jan 1, 2009	Panic Disorder
NCT00531895	Approved	Completed	Apr 1, 2006	Mar 1, 2007	Major Depression
NCT00322621	Approved	Completed	Apr 1, 2006	Oct 1, 2007	Diabetic Neuropathies
NCT01035073	Approved	Completed	Apr 1, 2006	May 1, 2009	Major Depressive Disorder

Competing Products

17 competing products in Obsessive Compulsive Disorder

See all competitors

Product	Company	Stage	Hype Score
Fluvoxamine maleate + Placebo	AbbVie	Phase 3	40
quetiapine fumarate + SSRI/Clomipramine	AstraZeneca	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	35
Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)	Novartis	Approved	43
Bitopertin + Placebo + SSRI	Roche	Phase 2	35
sertraline	Pfizer	Pre-clinical	26
pregabalin + Placebo	Pfizer	Approved	43
Sertraline + Levetiracetam + Placebo	UCB	Phase 2/3	30
Escitalopram	Lundbeck	Approved	36
Escitalopram + Placebo oral tablet	Lundbeck	Approved	44
Valbenazine + Placebo	Neurocrine Biosciences	Phase 2	39
RG1068 (Synthetic Human Secretin)	Repligen	Phase 2	32
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 2/3	32
Troriluzole (BHV-4157)	Biohaven	Phase 3	26
Nitrous Oxide + Nitrogen	Brain Biotech	Phase 2	32